GlaxoSmithKline News and Research

RSS

Cervical cancer vaccines in development

Two preventative vaccines, Gardasil (Merck) and Cervarix (GlaxoSmithKline) that work against the Human Papilloma virus (HPV) - a sexually transmitted infection and the primary cause of cervical cancer - are gaining favorable attention.

27 Feb 2006

Bristol-Myers Squibb agrees to record securities litigation settlement with sweeping drug disclosure requirements announces Labaton Sucharow

After prosecuting the securities litigation claims against Bristol-Myers Squibb Co. (BMS) for over five years, Labaton Sucharow, Lead Counsel representing the class and Lead Plaintiff, the LongView Collective Investment Fund of the Amalgamated Bank, reached an agreement in principle to settle the claims for $185 million in addition to meaningful corporate governance reforms that will affect future consumers and investors alike.

23 Jan 2006

Chemical warfare agent detection technology used to treat lung disease

A new technique based on the same technology used to detect chemical warfare agents and explosives is being employed by scientists at The University of Manchester to treat hospital patients with lung disease.

From The University of Manchester 23 Jan 2006

Experts demand more funds to stop the spread of bird flu

At a meeting in Beijing to whip up funds for the global fight against bird flu, the European Union has raised its contribution to the fund by $20 million taking their total commitment to $120 million, but other contributions appear to be thin on the ground.

18 Jan 2006

Anti-Obesity diet drug from cannabis works!

For those whose New Year's resolution was to yet again try to lose those extra kilos help may be at hand in the form of a new wonder drug derived from cannabis.

17 Jan 2006

European Medicines Agency receives first pandemic influenza vaccine application

The European Medicines Agency has received the first application for a pandemic influenza vaccine, submitted by GlaxoSmithKline Biologicals.

10 Jan 2006

Data establishes safety profile of new GlaxoSmithKline rotavirus vaccine candidate

Data from one of the largest infant vaccine trials ever conducted, published in the New England Journal of Medicine (NEJM), showed GlaxoSmithKline's (GSK) rotavirus vaccine candidate as effective against rotavirus disease (rotavirus gastroenteritis) in the first year of life. Rotavirus is the leading recognized cause of diarrhea-related illness and death among infants and young children.

6 Jan 2006

Rotateq eliminates the most severe cases of rotavirus

In a study of more than 68,000 infants published in the New England Journal of Medicine, the investigational vaccine Rotateq demonstrated that it can safely prevent 98 percent of severe cases of viral diarrhea and vomiting that account for 2 million hospital visits and 500,000 pediatric deaths each year worldwide.

6 Jan 2006

NEJM rotavirus studies: statement by PATH's Rotavirus Vaccine Program

On Thursday, January 5, the New England Journal of Medicine published the results of two important clinical trials of rotavirus vaccines.

4 Jan 2006

Sanofi's human bird flu vaccine tests looking good

French drug company Sanofi Pasteur says early stage trials of an experimental vaccine against H5N1 bird flu have shown it provides a good immune response in humans and is safe.

19 Dec 2005

Good results with cervical cancer vaccine in young girls

Drug company GlaxoSmithKline have had a good result with their new vaccine which was designed to prevent infection with the virus that causes cervical cancer.

19 Dec 2005

Nasal flu vaccine just as safe as a jab

According to U.S. government researchers, a new nasal vaccine against influenza, which helps patients avoid the needle, has caused no unexpected side-effects.

7 Dec 2005

University of Nottingham academic awarded prestigious professorship for research into lung disease

An academic at The University of Nottingham has been awarded a unique professorship by a leading national charity in recognition of his research, which aims to improve the medical care of patients with lung disease and respiratory infections.

30 Nov 2005

Drug partners in fight against AIDS say measles shot could be the answer!

Major drug company GlaxoSmithKline is hoping to develop an experimental AIDS vaccine by "piggy-backing" on a shot against measles.

29 Nov 2005

Star anise sought after in bird flu fight

The ancient spice star anise is apparently the main source of shikimic acid, a key ingredient in the bird flu drug Tamiflu, and farmers in China's southern region of Guangxi are being encouraged to capitalise on the growing demand for the spice.

28 Nov 2005

New drug far more effective in stopping smokers lighting up

An experimental smoking cessation drug by Pfizer apparently gives smokers better odds at kicking the habit.

16 Nov 2005

Adverts for SSRI antidepressants misleading

Consumer ads for a class of antidepressants called SSRIs often claim that depression is due to a chemical imbalance in the brain, and that SSRIs correct this imbalance, but these claims are not supported by scientific evidence, say researchers in PLoS Medicine.

13 Nov 2005

Updated vaccine against cervical cancer provides longer sustainable response

Drug company GlaxoSmithKline says that it's updated vaccine against the human papillomavirus (HPV), has produced a stronger immune response, than the original formula of the vaccine.

2 Nov 2005

$107.6 million grant for malaria vaccine candidate

In an important step toward developing an effective malaria vaccine, the Bill & Melinda Gates Foundation has announced a $107.6 million grant to the PATH Malaria Vaccine Initiative (MVI) to extend the public-private partnership between MVI and GlaxoSmithKline Biologicals (GSK Bio) to develop GSK Bio's malaria vaccine for children in Africa.

30 Oct 2005

As Europe panics, global co-operation urged in the fight against birdflu

As the panic about bird flu spreads across Europe, EU foreign ministers are urging global cooperation in efforts to tackle the threat of the deadly virus.

19 Oct 2005